Use Of First-Line Chemotherapy For Advanced Pancreatic Cancer: Folfirinox Versus Gemcitabine-Based Therapy.

4132 Background: Pancreatic cancer (PC) is the fourth leading cause of death in the United States. It is estimated that 46,420 patients will be diagnosed in 2014 and 35,590 will die (Siegel, CA Cancer J Clin 2014). Gemcitabine has long been the standard of care chemotherapy. Recent advances in treatment created the combination regimens (oxaliplatin, irinotecan, leucovorin, fluorouracil [FOLFIRINOX]) and gemcitabine, nab-paclitaxel (GN) for patients with good Karnofsky performance status (PS) (Conroy, NEJM 2011; Von Hoff, NEJM 2013). This retrospective analysis was conducted as an update to results reported at ASCO 2013 (Cartwright, JCO 2013) to evaluate characteristics and overall survival (OS) of patients receiving FOLFIRINOX and gemcitabine-based treatments in a large outpatient community setting. This is the largest study describing FOLFIRINOX patients to date. Methods: Patients with advanced PC treated at practices in The US Oncology Network entered into the iKnowMed (iKM) database between June 2010 a...